Relief as Apex Indian court seeks details on trial safeguards
This article was originally published in Scrip
Executive Summary
In what perhaps will come as a significant relief for industry, the Supreme Court order in a case concerning clinical trials in India appears less harsh than originally made out to be, with the apex court only seeking certain details on how the current regime safeguards trial participants with reference to the clearances granted for 162 proposals by the Drugs Controller General of India (DCGI).
You may also be interested in...
Sun Loses Shine Amid Testing Times In US
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
Top-Level Churn At Cipla's India Business
A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.
Need a specific report? 1000+ reports available
Buy Reports